DK3083633T3 - Spiro-oxazoloner - Google Patents

Spiro-oxazoloner

Info

Publication number: DK3083633T3
Authority: DK; Denmark
Prior art keywords: oxazolones; disorders; spiro; present; vasopressin
Prior art date: 2013-12-19

Application number

DK14815318.2T

Other languages

English (en)

Inventor

Valerie Runtz-Schmitt

Patrick Schnider

Cosimo Dolente

Bernhard Fasching

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-19

Filing date

2014-12-16

Publication date

2018-01-29

2014-12-16 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2018-01-29 Application granted granted Critical

2018-01-29 Publication of DK3083633T3 publication Critical patent/DK3083633T3/da

Links

239000003814 drug Substances 0.000 abstract 2
206010001488 Aggression Diseases 0.000 abstract 1
208000019901 Anxiety disease Diseases 0.000 abstract 1
208000019888 Circadian rhythm sleep disease Diseases 0.000 abstract 1
208000020401 Depressive disease Diseases 0.000 abstract 1
208000001456 Jet Lag Syndrome Diseases 0.000 abstract 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
102000002852 Vasopressins Human genes 0.000 abstract 1
108010004977 Vasopressins Proteins 0.000 abstract 1
230000016571 aggressive behavior Effects 0.000 abstract 1
208000012761 aggressive behavior Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
208000029560 autism spectrum disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000010363 phase shift Effects 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1
208000019116 sleep disease Diseases 0.000 abstract 1
-1 their manufacture Substances 0.000 abstract 1
229960003726 vasopressin Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

DK14815318.2T 2013-12-19 2014-12-16 Spiro-oxazoloner DK3083633T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP13198604		2013-12-19
PCT/EP2014/077858 WO2015091411A1 (en)	2013-12-19	2014-12-16	Spiro-oxazolones

Publications (1)

Publication Number	Publication Date
DK3083633T3 true DK3083633T3 (da)	2018-01-29

Family

ID=49876427

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14815318.2T DK3083633T3 (da)	2013-12-19	2014-12-16	Spiro-oxazoloner

Country Status (34)

Country	Link
US (4)	US10479796B2 (da)
EP (1)	EP3083633B1 (da)
JP (1)	JP6530407B2 (da)
KR (1)	KR102353431B1 (da)
CN (1)	CN105814062B (da)
AR (1)	AR098783A1 (da)
AU (1)	AU2014364729B2 (da)
BR (1)	BR112016013058B1 (da)
CA (1)	CA2932063C (da)
CL (1)	CL2016001495A1 (da)
CR (1)	CR20160215A (da)
DK (1)	DK3083633T3 (da)
EA (1)	EA029167B1 (da)
ES (1)	ES2657994T3 (da)
HR (1)	HRP20180160T1 (da)
HU (1)	HUE036203T2 (da)
IL (1)	IL245464B (da)
LT (1)	LT3083633T (da)
MA (1)	MA39139B1 (da)
MX (1)	MX370663B (da)
MY (1)	MY177313A (da)
NO (1)	NO3083633T3 (da)
NZ (1)	NZ719765A (da)
PE (1)	PE20160864A1 (da)
PH (1)	PH12016500919B1 (da)
PL (1)	PL3083633T3 (da)
PT (1)	PT3083633T (da)
RS (1)	RS56791B1 (da)
SG (1)	SG11201604915PA (da)
SI (1)	SI3083633T1 (da)
TW (1)	TWI548639B (da)
UA (1)	UA117273C2 (da)
WO (1)	WO2015091411A1 (da)
ZA (1)	ZA201603221B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201600522A (zh) *	2014-02-20	2016-01-01	赫孚孟拉羅股份公司	螺－唑酮
WO2017191117A1 (en)	2016-05-03	2017-11-09	Bayer Pharma Aktiengesellschaft	V1a receptor antagonists for use in the treatment of renal diseases
CN118251396A (zh)	2021-11-19	2024-06-25	豪夫迈·罗氏有限公司	2'-(7,7-二甲基-1'H,7H-螺[呋喃并[3,4-b]吡啶-5,4'-哌啶]-1'-基)-1,3-二氢-4'H-螺[茚-2,5'-[1,3]噁唑]-4'-酮的合成及其结晶形式
WO2025104154A1 (en)	2023-11-16	2025-05-22	F. Hoffmann-La Roche Ag	5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives as mmp9 inhibitors for the treatment of dry eye disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE433971T1 (de) *	2002-11-29	2009-07-15	Banyu Pharma Co Ltd	Neue azolderivate
US7351706B2 (en)	2006-01-05	2008-04-01	Hoffmann-La Roche Inc.	Indol-3-yl-carbonyl-spiro-piperidine derivatives
BRPI0720246A2 (pt) *	2006-12-07	2013-12-31	Hoffmann La Roche	Derivados de espiro-piperidina
CN101563323B (zh) *	2006-12-22	2012-07-04	弗·哈夫曼-拉罗切有限公司	螺-哌啶衍生物
ATE536356T1 (de) *	2007-01-12	2011-12-15	Hoffmann La Roche	Spiropiperidin-glycinamid-derivate
PE20110537A1 (es) *	2008-11-13	2011-08-04	Hoffmann La Roche	ESPIRO-5,6-DIHIDRO-4H-2,3,5,10B-TETRAAZA-BENZO[E]AZULENOS COMO ANTAGONISTAS DE LA V1a

2014
- 2014-12-16 SG SG11201604915PA patent/SG11201604915PA/en unknown
- 2014-12-16 RS RS20180097A patent/RS56791B1/sr unknown
- 2014-12-16 JP JP2016541359A patent/JP6530407B2/ja active Active
- 2014-12-16 EA EA201691189A patent/EA029167B1/ru not_active IP Right Cessation
- 2014-12-16 WO PCT/EP2014/077858 patent/WO2015091411A1/en not_active Ceased
- 2014-12-16 EP EP14815318.2A patent/EP3083633B1/en active Active
- 2014-12-16 MY MYPI2016001019A patent/MY177313A/en unknown
- 2014-12-16 SI SI201430574T patent/SI3083633T1/en unknown
- 2014-12-16 MX MX2016007809A patent/MX370663B/es active IP Right Grant
- 2014-12-16 AU AU2014364729A patent/AU2014364729B2/en active Active
- 2014-12-16 BR BR112016013058-8A patent/BR112016013058B1/pt active IP Right Grant
- 2014-12-16 PE PE2016000722A patent/PE20160864A1/es unknown
- 2014-12-16 CA CA2932063A patent/CA2932063C/en active Active
- 2014-12-16 ES ES14815318.2T patent/ES2657994T3/es active Active
- 2014-12-16 HR HRP20180160TT patent/HRP20180160T1/hr unknown
- 2014-12-16 MA MA39139A patent/MA39139B1/fr unknown
- 2014-12-16 CN CN201480067988.1A patent/CN105814062B/zh active Active
- 2014-12-16 UA UAA201607813A patent/UA117273C2/uk unknown
- 2014-12-16 KR KR1020167019366A patent/KR102353431B1/ko active Active
- 2014-12-16 NO NO14815318A patent/NO3083633T3/no unknown
- 2014-12-16 LT LTEP14815318.2T patent/LT3083633T/lt unknown
- 2014-12-16 DK DK14815318.2T patent/DK3083633T3/da active
- 2014-12-16 PT PT148153182T patent/PT3083633T/pt unknown
- 2014-12-16 PL PL14815318T patent/PL3083633T3/pl unknown
- 2014-12-16 HU HUE14815318A patent/HUE036203T2/hu unknown
- 2014-12-16 NZ NZ719765A patent/NZ719765A/en unknown
- 2014-12-17 AR ARP140104703A patent/AR098783A1/es active IP Right Grant
- 2014-12-18 TW TW103144383A patent/TWI548639B/zh active
2016
- 2016-05-03 IL IL24546416A patent/IL245464B/en active IP Right Grant
- 2016-05-05 CR CR20160215A patent/CR20160215A/es unknown
- 2016-05-12 ZA ZA2016/03221A patent/ZA201603221B/en unknown
- 2016-05-18 PH PH12016500919A patent/PH12016500919B1/en unknown
- 2016-06-06 US US15/174,674 patent/US10479796B2/en active Active
- 2016-06-15 CL CL2016001495A patent/CL2016001495A1/es unknown
2019
- 2019-10-08 US US16/596,293 patent/US11578077B2/en active Active
2022
- 2022-11-29 US US18/059,554 patent/US12162887B2/en active Active
2024
- 2024-11-04 US US18/936,608 patent/US20250066378A1/en active Pending

Also Published As

Publication number	Publication date
BR112016013058B1 (pt)	2021-02-23
MX370663B (es)	2019-12-19
UA117273C2 (uk)	2018-07-10
CR20160215A (es)	2016-07-15
PT3083633T (pt)	2018-01-25
CN105814062A (zh)	2016-07-27
US11578077B2 (en)	2023-02-14
US20250066378A1 (en)	2025-02-27
MX2016007809A (es)	2016-09-07
PH12016500919A1 (en)	2016-06-27
US12162887B2 (en)	2024-12-10
TWI548639B (zh)	2016-09-11
ES2657994T3 (es)	2018-03-07
US10479796B2 (en)	2019-11-19
AR098783A1 (es)	2016-06-15
PE20160864A1 (es)	2016-09-03
US20230106150A1 (en)	2023-04-06
HRP20180160T1 (hr)	2018-02-23
IL245464B (en)	2019-10-31
LT3083633T (lt)	2018-02-12
SG11201604915PA (en)	2016-07-28
JP2017502028A (ja)	2017-01-19
SI3083633T1 (en)	2018-02-28
TW201536790A (zh)	2015-10-01
IL245464A0 (en)	2016-06-30
KR102353431B1 (ko)	2022-01-20
KR20160098490A (ko)	2016-08-18
AU2014364729A1 (en)	2016-05-26
NO3083633T3 (da)	2018-04-28
WO2015091411A1 (en)	2015-06-25
ZA201603221B (en)	2022-05-25
PH12016500919B1 (en)	2016-06-27
MY177313A (en)	2020-09-11
RS56791B1 (sr)	2018-04-30
MA39139A1 (fr)	2018-05-31
US20200039997A1 (en)	2020-02-06
US20170008901A1 (en)	2017-01-12
EP3083633A1 (en)	2016-10-26
EP3083633B1 (en)	2017-11-29
AU2014364729B2 (en)	2018-11-22
EA029167B1 (ru)	2018-02-28
PL3083633T3 (pl)	2018-04-30
HUE036203T2 (hu)	2018-06-28
JP6530407B2 (ja)	2019-06-12
CN105814062B (zh)	2018-04-24
NZ719765A (en)	2022-04-29
CL2016001495A1 (es)	2016-12-16
CA2932063A1 (en)	2015-06-25
HK1223920A1 (zh)	2017-08-11
EA201691189A1 (ru)	2016-10-31
MA39139B1 (fr)	2019-01-31
CA2932063C (en)	2023-03-07

Publication	Publication Date	Title
CL2014002334A1 (es)	2015-04-17	Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
EP2852886A4 (en)	2016-02-17	LAYERING CROSS-CRACKING TROUBLESHOOTING AT ONE APPLICATION DELIVERY
CR20140259A (es)	2014-08-21	Compuestos novedosos de benzopirano, composiciones y usos de los mismos
DK3520805T3 (da)	2021-04-19	Sammensætninger til behandling af myelofibrose
WO2013151668A3 (en)	2013-12-19	Modified polynucleotides for the production of secreted proteins
HK1206612A1 (en)	2016-01-15	Modified polynucleotides for the production of secreted proteins
EP2940131A4 (en)	2016-06-01	AAV VARIANT
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
DK2718404T3 (da)	2021-04-26	Fremgangsmåde til fremstilling af flydende carbonhydrider
EP3604536C0 (en)	2024-05-29	RNA MODULATING OLIGONUCLEOTIDES WITH ENHANCED CHARACTERISTICS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
SI2922526T1 (sl)	2022-01-31	Proizvodnja polplastičnih farmacevtskih odmernih enot
MY177031A (en)	2020-09-02	Tetrahydropyridopyrazines modulators of gpr6
EP3273945C0 (en)	2024-07-10	CONTINUOUS PRODUCTION OF PARTICLES
DK2635282T3 (da)	2022-10-17	Sammensætninger til behandling af myelofibrose
IL246985B (en)	2021-04-29	stable liquid preparations
EP2694964A4 (en)	2014-10-29	HIGH-SPEED SCREENING FOR COMPOUNDS FOR MODULATING THE EXPRESSION OF CELLULAR MACROMOLECULES
DK3021839T3 (da)	2021-07-26	Sammensætninger for behandling af fibrose
EP2825610A4 (en)	2016-03-09	STABILIZED IODOCALINE COMPOSITIONS
EA201590932A1 (ru)	2015-10-30	Композиции, содержащие вортиоксетин и донепезил
EP3194027C0 (en)	2026-02-11	COMPOSITIONS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
PH12016500919B1 (en)	2016-06-27	Spiro-oxazolones
DK2705847T3 (da)	2014-10-06	Sammensætning til behandling af psoriasis
MX2014003600A (es)	2014-04-25	Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a.
MX366607B (es)	2019-07-16	Espiro-oxazolonas.
CL2015000580A1 (es)	2015-07-10	Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros.